knowledge -WSS

knowledge

author：comprehensive 2025-09-06 03:17:18 - browse：851

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Search called off for baby washed away in Pennsylvania flash flood

entertainment

WSS

Study: Pain burden is higher in Black NFL players than white ones

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Lecanemab for Alzheimer's is coming. Is the health system ready?

Rise in cancer among younger people worries and puzzles doctors

CDC Director Mandy Cohen on transparency, trust, and health

Dems pitch expanding Medicare power to negotiate drug prices

entertainment

knowledge

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Why 40% Americans with Parkinson’s don’t see a neurologist

Apple is now the first public company to be valued at $3 trillion

Device maker Teleflex to acquire urology company for $600M

George Santos makes 1st court appearance after pleading not guilty to 13 counts

It's time to get medical device identifiers over the finish line

Dobbs anniversary: the lost opportunity of abortion as health care

Biden warns of ‘dark winter’ during final presidental debate

Hepatitis C has a cure — but many Americans still lack access to it

Living with Fabry disease, a condition that causes chronic pain

explore

Former reverend arrested for allegedly killing 8

Biogen says it will cut costs by $700 million, slash 1,000 jobs

'Investigate these claims': UFO transparency at center of House hearing

NIH fellows want a pay raise. Will that mean less money for grants?

Device maker Teleflex to acquire urology company for $600M

Retired US general questions alleged Putin, Prigozhin meeting

leisure time

leisure time

entertainment

knowledge